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ABSTRACT Bronchiectasis is an increasing clinical problem, but multiple recent clinical trials have failed
to reach their primary end-point. Difficulties in achieving “positive” bronchiectasis trials is reflected in a
lack of agreement from trialists and regulators on what are the optimal end-points.
To evaluate the use of end-points in bronchiectasis trials, we conducted a systematic review of published
bronchiectasis trials from 2008 to 2018 and extracted end-points used, definitions, methods of analysis and
responsiveness.
Our analysis shows that quality of life and exacerbation end-points are most frequently used. Trials
using exacerbation end-points have been characterised by varying definitions, multiple methods of analysis
and durations of follow-up. There are multiple quality of life tools for bronchiectasis (Quality of Life –
Bronchiectasis questionnaire, St George’s Respiratory Questionnaire, etc.). The majority of studies measure
lung function (e.g. forced expiratory volume in 1 s), but this is shown to be nonresponsive to the majority
of interventions. Microbiology end-points frequently show statistically significant differences in phase 2
antibiotic studies but their correlation with clinical end-points is unknown.
This systematic review demonstrates a need for guidance to standardise definitions and design features
to improve reproducibility and increase the likelihood of demonstrating statistically significant benefits
with new therapies.
Introduction
Bronchiectasis is a chronic respiratory disease that causes persistent cough, sputum production and
recurrent chest infections. It can be caused by a variety of genetic, autoimmune, inflammatory, allergic and
degenerative conditions. The prevalence of bronchiectasis is increasing worldwide [1, 2].
Bronchiectasis is an orphan disease with few randomised controlled trials (RCTs) having been conducted
and a limited understanding of its pathophysiology. The 2017 European Respiratory Society (ERS)
guidelines for bronchiectasis were unable to recommend any pharmacotherapy with strong evidence
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because of a lack of trials demonstrating statistically significant benefits [3]. In contrast, there have been
many randomised trials in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) over
the past 20 years, leading to a tendency for bronchiectasis researchers to use end-points and therapies
previously developed in these two diseases. The failure of some therapies to show benefit in bronchiectasis,
notably recombinant DNAse in the late 1990s, has led many to suggest this approach is flawed and that
specific trial end-points and approaches are needed for bronchiectasis [4].
The US Food and Drug Administration (FDA) defines a valid end-point as something that measures how a
patient “feels, functions or survives”. To license a medication, the FDA requires substantial evidence of efficacy
and safety which usually means demonstrating statistically significant benefits versus placebo in terms of the
primary end-point and no major issues with safety. European regulators have similar requirements [5]. In
addition, substantial evidence of efficacy usually requires consistency of effect in two well-controlled RCTs [6].
Inhaled antibiotics, macrolides, mucoactive drugs, chest physiotherapy, pulmonary rehabilitation and
anti-inflammatory drugs are all used in clinical practice and many are believed to benefit patients. Few
have shown consistent benefit in large randomised trials. The reasons for this may be that the population
most likely to benefit has not been identified or that the optimal end-points and end-point definitions
have not been identified. The repeated challenges encountered in bronchiectasis trials requires a thorough
re-evaluation of the selected end-points, their definitions and other aspects of trial design.
In this study, we conducted a systematic review of the end-points used in bronchiectasis clinical trials with
the goal of identifying the most widely used end-points, their definitions and responsiveness, and of
identifying research priorities for optimising pharmacotherapy trials.
Methods
Search strategy
A systematic review was conducted on the reporting of RCTs in bronchiectasis and is reported according to
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched
PubMed using the keyword “bronchiectasis” and filtering for clinical trials in humans, published in English,
published between January 01, 2008 and July 31, 2018. This search was supplemented using the
COCHRANE ultra-sensitivity search: (((((randomised controlled trial[pt] OR controlled clinical trial[pt] OR
randomised[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti]
NOT (animals[mh] NOT humans [mh])))) AND “bronchiectasis” AND (“2008/01”[Date – Publication] :
“2018/07”[Date - Publication])).
An EMBASE sensitivity search was also conducted using the same criteria.
The review was registered with PROSPERO (www.crd.york.ac.uk/prospero) with identifier number
CRD42018106167).
Inclusion criteria
The review included RCTs defined as per the International Committee of Medical Journal Editors
definition [7]. This includes parallel group, crossover or any other controlled trial design. Studies enrolling
a minimum of 25 participants were selected as adequately powered efficacy and safety studies. For this
review, only studies including patients aged 18 years and over and diagnosed with bronchiectasis not
related to CF were included. The interventions may include inhaled antibiotics, macrolides, mucoactive
drugs or anti-inflammatory therapies. We excluded trials testing dietary, exercise or physiotherapy
interventions as the objective of the study is to examine end-points specifically for pharmacotherapy
trials. We included studies where the control was placebo, no intervention, standard care or an active
comparator, but excluded studies without a control group. Studies which included more than one disease
where the bronchiectasis cohort could not be clearly separated were excluded, as were secondary analyses
of previously reported studies and those which only reported laboratory or experimental end-points as the
review focused on end-points with the potential for clinical benefit.
For data extraction, articles were reviewed by two independent reviewers and confirmed by a third.
Extracted data included end-points used, method of assessment and the definition of end-point assessment
(where necessary). Trials were classified as “positive” or “negative” depending on whether there was a
statistically significant difference between intervention and control in the primary outcome. Trials where
the primary outcome was positive but there were significant findings in adverse events and/or patient safety
were classified as “negative” overall. Any disagreements between reviewers were resolved by discussion.
Outcomes
The main aim of this review was to identify the most commonly used end-points in randomised
controlled pharmacotherapeutic trials of bronchiectasis. Once established, these were analysed for
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responsiveness, defined as demonstration of statistically significant differences between groups, and
consistency of definition across trials.
Statistical analysis
A priori, we determined that no meta-analysis would be undertaken. Data were collected and reported into
tables for each individual trial and then summarised by end-point. For analysis purposes end-points were
grouped into end-point categories: exacerbation, microbiological, sputum characteristics, lung function,
health-related quality of life (HRQoL) and biomarkers. For example, forced expiratory volume in 1 s
(FEV1) and peak flow rate would be grouped as lung function end-points, frequency and time to first
exacerbation would be grouped as exacerbation end-points and patient-reported outcomes would be
grouped under HRQoL. A further category “other” was added to capture less frequently used end-points
such as changes to nitric oxide levels and radiological changes.
A further search of clinicaltrials.gov and ISRCTN (www.isrctn.com) was made to capture any trials that
may have been conducted within our review period and that may not have been published. We identified 81
studies, of which 70 were excluded as they were published (n=14), did not relate specifically to
bronchiectasis (n=15), were outside the study period (n=2), had a study population less than 25 (n=2) or
were not a pharmacotherapeutic agent (n=37). The 11 remaining trials (table 1) were eligible for our review
but were unpublished and could not be fully analysed, suggesting that at least a third of bronchiectasis
research data is not being made available. Similar to the main analysis, the most frequently used primary
end-point (n=12) was exacerbations (n=5) and the most commonly used end-point overall (n=34) was lung
function (n=8), closely followed by health-related quality of life (HRQoL) questionnaires (n=7).
TABLE 1 Summary of randomised controlled trials found not to be published (2008–2018)
NCT number Trial title Year# Phase Primary
end-point
group(s)
Secondary end-point group(s)
NCT00775138 A study to determine the safety and tolerability of
arikace versus placebo in patients who have
bronchiectasis
2008–2009 2 Lung function,
other
Lung function, microbiology,
HRQoL
NCT01677403 A study to access safety and efficacy of nebulized
tobramycin in patients with bronchiectasis
2012–2014 4 Microbiology Sputum, lung function, HRQoL
NCT01684683 The effect of theophylline in the treatment of
bronchiectasis
2012–2014 4 HRQoL Exacerbations, sputum,
HRQoL, lung function,
microbiology, biomarkers,
other
NCT01580748 Phase 2, single group, open clinical trial to
evaluate the efficacy and safety of roflumilast in
symptomatic bronchiectasis patients
2012–2013 2 HRQoL Lung function, biomarkers
NCT01818544 Safety and efficacy of oral BAY85–8501 in patients
with non-CF (cystic fibrosis) bronchiectasis
2013–2014 2 Other Lung function, HRQoL,
sputum, biomarkers
NCT01769898 The role of theophylline plus low-dose
formoterol-budesonide in treatment of
bronchiectasis
2013–2014 4 HRQoL Exacerbations, sputum, lung
function, biomarkers
NCT02088216 Effect of long-term, high-dose N-acetylcysteine
on exacerbations of bronchiectaisis (BENE)
2014–2016 4 Exacerbations Sputum, exacerbations, lung
function, HRQoL, other
NCT02104245 Phase 3 study with ciprofloxacin dispersion for
inhalation in non-CF bronchiectasis (ORBIT-4)
2014–2016 3 Exacerbations No information
NCT01515007 Phase 3 study with ciprofloxacin dispersion for
inhalation in non-CF bronchiectasis (ORBIT-3)
2014–2016 3 Exacerbations No information
NCT02546297 Comparisons of inhaled LAMA or ICS+LABA for
COPD with bronchiectasis
2015–2017 4 Exacerbations Lung function, HRQoL, other
NCT02507843 Vitamin D as an adjunctive treatment in patients
with non-cystic fibrosis bronchiectasis (VIDB)
2015–2017 4 Exacerbations Exacerbations, HRQoL, other
All trials were registered at clinicaltrials.gov. Primary end-points (n=12): exacerbations (n=5), health-related quality of life (HRQoL) (n=3),
microbiology (n=1), other (n=2) and lung function (n=1). Secondary end-points (n=34): lung function (n=8), HRQoL (n=7), sputum (n=5),
exacerbations (n=4), biomarkers (n=4), other (n=4) and microbiology (n=2). “Other” end-points include FACED score, vital signs and adverse
events. LAMA: long-acting muscarinic antagonists; ICS: inhaled corticosteroid; LABA: long-acting β-agonists; COPD: chronic obstructive
pulmonary disease. #: it is recommended that trials are reported within 1 year of completion, and so trials are listed here if completed earlier
than November 2017.
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Results
Selection process
The primary search identified 118 papers. Following exclusion of 52 studies which were not specific to
bronchiectasis, five paediatric studies, 38 non-pharmacotherapy trials and four studies which involved
recruitment of less than 25 participants, the remaining 19 studies were eligible for end-point analysis.
The additional Cochrane ultra-sensitive search in PubMed identified 225 manuscripts of which only a
further five were eligible for inclusion in this review. The EMBASE search did not identify any additional
eligible trials.
The final 24 trials are analysed as 23 trials, as two replicate trials were described in two manuscripts but
as these trials ran in parallel using an identical protocol they are reported together [8, 9]. Figure 1 shows
the flow of study selection using the above criteria, while figure 2 shows the chronological progress of
publications on pharmacotherapeutic RCTs in bronchiectasis from 2008.
Studies
23 RCTs were identified meeting the review inclusion criteria. The shortest trial duration was 26 days for a
crossover study looking at the effects of 7% hypertonic saline versus hyaluronic acid [10], while the longest
trials were all antibiotic interventions for 15 months [11–13]. The inclusion criteria for this review required a
minimum 25 participants in the trial, of the 23 RCTs reviewed the minimum study population was 28 [10, 14]
while the largest study included 937 participants globally across two replicate trials [8, 9]. To categorise each
trial by intervention: we reviewed 13 antibiotic trials, five mucolytic/mucoactive drug trials and five
anti-inflammatory drug trials. Macrolides are typically referred to as both antibiotic and anti-inflammatory.
We classified them as antibiotics for the purposes of analysis, except in one case where the investigators
specifically referred to the trial as testing the anti-inflammatory effect [15]. Table 2 shows an overview of the
selected trials used in this review and the end-points which each trial used grouped into seven main categories.
Current end-points
Of the 23 RCTs identified by our search, we counted 31 primary end-points (five studies used co-primary
end-points: HERNANDO et al. [17], BILTON et al. [20] and LIU et al. [15] each used two, WONG et al. [18]
Initial search: PubMed
Clinical trials in humans 
published in English
between 2008–2018
"bronchiectasis"
Number of
patients/records identified
n=118
Studies included
n=24
Mucoactive drugs
n=5
Anti-inflammatory drugs
n=5
Antimicrobial drugs
n=14#
Additional trials found
from Cochrane ultra-
sensitive review and 
EMBASE review
n=5
Non-bronchiectasis specific n=52
Not a randomised controlled drug trial     
  (protocol, sub-study etc.) n=38
Study in children n=5
Sample size <25 n=4
FIGURE 1 Flow diagram of the study selection process. #: antimicrobial drugs trials n=14, were analysed as
n=13 due to combined analysis of two manuscripts.
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measured three, while STOCKLEY et al. [19] used four). 14 of these primary end-points demonstrated a
statistically significant difference versus placebo or control (48%). Accounting for the study by WONG et al. [18]
using multiple primary end-points, 12 out of 23 studies successfully met their primary end-points. Of all
107 end-points reviewed, a total of 37 demonstrated statistically significant differences versus placebo or
control (table 3).
Reviewing the trials by type of intervention, we see that antibiotic trials favour primary end-points in
exacerbations and microbiology and are quite frequently successful in phase 2, whereas primary end-points
in HRQoL rarely demonstrate benefits (table 4). Anti-inflammatory trials trend towards biomarker
end-points and symptoms. The majority of trials were not successful in lung function end-points and had
low success in all other categories. The mucoactive drug trials showed few positive results in all end-point
categories with only 18% of their end-points showing statistically significant differences.
In the following sections, we report the findings of each defined end-point used in the aforementioned
eligible studies. The definition and method of assessment are detailed before discussing the experience of
using them in existing bronchiectasis clinical trials.
Individual end-points
Time to next exacerbation and exacerbation frequency
While reviewing the exacerbation end-points, we noted four different measures: time to next exacerbation,
number of subjects experiencing exacerbations, rate and duration, and with these came a variety of
methods for statistical analysis. Using exacerbation as a primary end-point had a similar (∼50%) success
rate as when used as a secondary end-point. In terms of primary end-points, attempting to reduce
exacerbation frequency is the most frequently used [8, 9, 12, 16, 22]. Throughout the review process we
identified many variations of a protocol-defined exacerbation and methods of corresponding analysis,
these can be seen in table 5. Definitions of exacerbation were highly variable between studies and many
criteria appeared to be subjective, for example, one study defined an exacerbation as an “increase in
dyspnoea, sputum production and sputum purulence”. Some definitions relied not only on a minimum
number of symptoms but also a minimum period of time experiencing them (varying up to 48 h). Other
studies had multiple definitions within the same protocol, some of which were relatively complex, where
investigators had to account for the previous week’s entries of a daily diary card [18]. Diary cards were
used in only two trials to assist symptom monitoring [12, 18]. Some studies did not use an exacerbation
definition but used a surrogate of “antibiotic use” as an isolated end-point. However, in some cases,
exacerbations could be diagnosed without a physician decision to treat while in others the symptom
definition had to be accompanied by a decision to prescribe antibiotics and/or corticosteroids.
Inclusion in exacerbation studies tends to rely on exacerbation history, i.e. it is assumed that a frequent
exacerbator in the previous year will exacerbate in the current year making this person the ideal candidate
for an exacerbation study. From 19 trials using exacerbation end-point criteria, 11 defined exacerbation
history as part of their protocol inclusion criteria and only two requested exacerbation history for more
than 12 months [16, 29].
6
7
5
4
3
2
1
0
R
CT
s 
n
Year
20122011201020092008 2013 2014 2015 2016 2017 2018
FIGURE 2 Number of published pharmacotherapeutic randomised controlled trials (RCTs) conducted since
2008.
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Recording of exacerbations requires a sufficiently long follow-up time to capture a meaningful number of
events. We found, however, that exacerbation end-points were also used in short studies where the chance
of a patient exacerbating within such a brief time frame is low [17, 20, 21, 23, 24]. From the trials reviewed,
TABLE 2 Summary of end-points for the articles eligible for review
Neutrophil elastase inhibitor 
(AZD9668), STOCKLEY [19]
Nebulised gentamicin
MURRAY [11]
Trial, first author [ref.] Exacer-
bations
Micro-
biology
Sputum Lung
function
HRQoL Bio-
markers
Other
7% hypertonic saline
KELLETT [14]
6% hypertonic saline
NICOLSON [16]
#
#
#
# #
#
#
# # #
# # #
#
#
#
#
# #
#
#
#
#
#
#
#
#
#¶
#¶
#¶
#+
Budesonide 
HERNANDO [17]
EMBRACE
WONG [18]
Mannitol
BILTON [20]
Ciprofloxacin DPI
WILSON [21]
BAT
ALTENBURG [12]
BLESS
SERISIER [22]
ORBIT-2
SERISIER [23]
Azithromycin
DE DIEGO [24]
Azithromycin
LOURDESAMY [28]
Inhaled mannitol
BILTON [29]
Roxithromycin
LIU [15]
Tobramycin
ORRIOLS [13]
STRATUS
DE SOYZA [30]
Inhaled colistin
HAWORTH [25]
Atorvastatin
MANDAL [26]
AIR-BX1 and AIR-BX2
BARKER [27]
RESPIRE I and II
DE SOYZA [8] and AKSAMIT [9]
Hyaluronic acid plus 7% hypertonic 
saline, HERRERO-CORTINA [10]
Nebulised amikacin
AILIYAER [31]
Green: end-point(s) passed; pink: end-point(s) failed; orange: not clear or mixed results. HRQoL: health-
related quality of life. #: primary end-point; ¶: safety issues; +: no clinical benefit.
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we noted eight with a maximum duration of 6 months which used various exacerbation end-points (one
of which was the primary). Shorter studies which use exacerbations as end-points fall into the bias of
recruitment periods, for example, a study running during a viral season or the winter months may have
a higher volume of exacerbations than when running during summer months suggesting exacerbation
frequency or time to next exacerbation may not be an ideal end-point for a short study. Of these eight
studies under discussion, five were analysing time to next exacerbation, two were analysing frequency
and the last was not clearly specified. There did not appear to be any preference as to which
exacerbation definition was used by each of the intervention groups (antibiotics, anti-inflammatories or
mucolytics). Methods of statistical analysis can have a major impact on the outcome of exacerbation
studies and we also identified a high degree of heterogeneity in the analysis methods used in
bronchiectasis trials (table 5).
Decrease in bacterial load or eradication of pathogens (predominantly Gram-negatives)
The most common microbes taken from positive cultures in bronchiectasis are Haemophilus influenzae
and Pseudomonas aeruginosa [3]. A reduction in sputum bacterial load by greater than or equal to one log
unit is deemed the minimum change necessary for clinical significance [32].
Microbiology as a primary end-point was exclusively used in antibiotic trials and demonstrated statistically
significant differences versus placebo or control in 100% of trials reviewed. When including studies that
used microbiology as a secondary end-point the success rate was 50% (table 3).
In general, antibiotic treatments do reduce bacterial load, as shown by positive results in six out of nine
microbiology end-points within the antibiotic trials. However, the value of this end-point is questioned as
it is not known to what extent reductions in bacterial load correlate with improvements in clinical
outcomes. Of the six trials we identified in which CFU reductions were demonstrated, only two had
positive HRQoL outcomes [11, 25] and three had positive exacerbation end-points [11, 13, 23].
Several studies have shown good reductions in bacterial load with no clear or consistent clinical efficacy
raising questions about the value of this standard end-point for phase 2 antibiotic trials [11, 21, 23, 25, 31].
Sputum colour or weight
For treatments that aim to improve lung clearance by way of sputum expectoration, there is a degree of
logic in trying to demonstrate that drugs increase the volume of sputum removed from the lungs. We
identified 13 studies that used sputum characteristics as an end-point. The typical sputum characteristics
were sputum volume, sputum weight and sputum colour.
TABLE 4 Summary of the end-points favoured by each type of intervention
Exacerbation-
related
Microbiology Sputum-
related
Lung
function
HRQoL Biomarkers
(blood and sputum)
Other
Antibiotic trials (n=13) Primary 3/5 5/5 1/1 0/1 0/2 N/A 0/1
Accumulative 7/11 6/9 4/7 2/10 5/13 1/6 1/5
Anti-inflammatory trials (n=5) Primary N/A N/A 0/1 0/2 1/2 2/4 1/2
Accumulative 1/4 0/1 1/2 0/4 2/5 2/5 1/3
Mucolytic trials (n=5) Primary 0/2 N/A 0/2 1/1 0/1 N/A N/A
Accumulative 1/4 0/2 0/4 1/5 2/5 0/1 0/1
Data are presented as n/N. HRQoL: health-related quality of life; N/A: not applicable.
TABLE 3 Summary of frequency with which trials met their end-points comparing active treatment with placebo or control in
each end-point category
End-point group Exacerbation-related Microbiology Sputum-related Lung function HRQoL Biomarkers
(blood and sputum)
Other
Primary end-points 3/7# 5/5 1/4 1/4 1/5 2/4 1/2
Accumulative end-points 9/19 6/12 5/13 3/19 9/23¶ 3/12 2/9
Data are presented as n/N. HRQoL: health-related quality of life. #: most commonly used primary end-point; ¶: most commonly used end-point
(primary and secondary).
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TABLE 5 Summary of the studies which looked at exacerbations as end-points, demonstrating that each study used a different
exacerbation definition with potential implications for the study results
Trial, first author [ref.] Exacerbation definition Method of assessment/measurement
Nebulised gentamicin,
MURRAY [11]
A clinical deterioration with all of the following: increasing cough,
increasing sputum volume and worsening sputum purulence
All patients subsequently received antibiotics for 14 days
TTF: median
Number: count
7% hypertonic saline,
KELLETT [14]
Unscheduled primary or secondary events leading to provision of rescue
medications, either steroid or antibiotic, Accident and Emergency
attendance or hospitalisation
Number: count
6% hypertonic saline,
NICOLSON [16]
⩾3 symptoms in 1 day for two or more consecutive days Number: median (IQR)
Budesonide,
HERNANDO [17]
Worsening of at least 3 out of 4 symptoms for at least 48 h Number: mean
Duration: mean
EMBRACE,
WONG [18]
Two definitions
Event-based exacerbation: an increase in or new onset of more than one
pulmonary symptom (sputum volume, sputum purulence, or dyspnoea)
requiring treatment with antibiotics
Symptom-based exacerbation: an increase in or new onset of more than
one pulmonary symptom reported on the daily diary card and the mean
of the three symptom scores from the daily diary card on two
consecutive days had to increase by at least one point (on a five-point
scale) compared with the same calculation 1 week earlier
Median TTF: Cox proportional hazard
presented as Kaplan–Meier plots
Number: rate ratio (Poisson regression
model frequency)
Mannitol,
BILTON [20]
Treated with parenteral antibiotics for any four of the following 12 signs or
symptoms: change in sputum; new or increased haemoptysis; increased
cough; increased dyspnoea; malaise, fatigue or lethargy; temperature
above 38°C; anorexia or weight loss; sinus pain or tenderness; change
in sinus discharge; change in physical examination of the chest;
decrease in pulmonary function by 10% or more from a previously
recorded value; or radiographic changes indicative of pulmonary
infection
TTF: presented as Kaplan–Meier plots
Ciprofloxacin DPI,
WILSON [21]
Not clear TTF: method not reported
BAT,
ALTENBURG [12]
Two definitions
Protocol defined exacerbation: at least four of the following nine
symptoms, signs or findings were present: 1) change in sputum
production (consistency, colour, volume or haemoptysis); 2) increased
dyspnoea (chest congestion or shortness of breath); 3) increased cough;
4) fever (>38°C); 5) increased wheezing; 6) decreased exercise
tolerance, malaise, fatigue or lethargy; 7) FEV1 or FVC decreased by at
least 10% from previous recorded value; 8) radiographic changes
indicative of a new pulmonary infectious process; or 9) changes in chest
sounds
Non-protocol defined exacerbation: fewer than four of the above
abnormalities
Number: median (IQR)
TTF: Cox proportional hazard
presented as Kaplan–Meier plots
BLESS,
SERISIER [22]
Antibiotic treatment for a sustained (more than 24 h) increase in sputum
volume or purulence accompanied by new deteriorations in at least two
additional symptoms: sputum volume, sputum purulence, cough,
dyspnoea, chest pain or haemoptysis
Number: rate ratio (Poisson regression
model frequency)
Frequency: rate ratio (Poisson
regression model frequency)
ORBIT-2,
SERISIER [23]
Deterioration in ⩾4 of the following nine signs or symptoms: sputum
production (volume, colour, consistency or haemoptysis), dyspnoea,
cough, fever, wheezing, exercise tolerance (or fatigue/lethargy/malaise),
FEV1 or FVC fall of at least 10%, new changes on chest radiograph and
changes in chest sounds on auscultation
Median TTF: Kaplan–Meier plot
Azithromycin,
DE DIEGO [24]
No definition stated Number: mean
Inhaled colistin,
HAWORTH [25]
Presence of ⩾3 of the following signs or symptoms for at least 24 h:
increased cough, increased sputum volume, increased sputum
purulence, haemoptysis, increased dyspnoea, increased wheezing, fever
(>38°C) or malaise, and the treating physician agreed that antibiotic
therapy was required
TTF: median (IQR) presented as
Kaplan–Meier plots
Atorvastatin,
MANDAL [26]
As per British Thoracic Society guidelines and treated them according to
baseline sputum bacteriological findings and administered 14 days of
oral antibiotic treatment
Frequency: median (IQR)
Continued
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There are known issues with the collection and characterisation of sputum including the high degree of
patient compliance required when collecting sputum over 24 h. Sputum weight can be affected by multiple
variables including weather, exercise, hydration status, diet and saliva contamination. The process of separating
the weight of sputum from the lungs (desirable) from the weight of saliva from the mouth (undesirable) has
not yet been standardised, and theoretically, some treatments that initially increase sputum weight because
they are clearing the lungs in the short term, may actually reduce sputum volume over the long term as lung
inflammation reduces. Examples of the challenges of using sputum weight were demonstrated in a study by
BILTON et al. [20], where mannitol was used for 12 weeks with the hypothesis this would increase sputum
weight compared with placebo. The sputum weight was significantly higher in the treatment group after
12 weeks, but primarily because sputum weight decreased in the placebo group, who had received more
antibiotics [20]. This study demonstrates that other factors, such as antibiotic use, can influence sputum
characteristics and make this a challenging end-point. We did not identify data on the variability of sputum
volume as an end-point in bronchiectasis or a minimal clinically important difference (MCID).
Spirometry
Improvements in FEV1 have historically been the primary outcome for most COPD and CF clinical trials
and a variety of drugs have consistently improved this end-point in those diseases. We found this was not
the case in bronchiectasis as it has been shown to be poorly responsive to multiple interventions. The reasons
for this are not clear and require further study. From the 23 studies reviewed, 19 had at least one end-point
related to improvements in spirometry; however, only three obtained a statistically significant beneficial
outcome. Four trials used lung function as the primary outcome, but only one had a positive outcome [28].
From the three trials showing a positive outcome in their lung function end-point, the variation in results
is remarkable. The BAT trial conducted by ALTENBURG et al. [12] in the Netherlands was a 12-month study
TABLE 5 Continued
Trial, first author [ref.] Exacerbation definition Method of assessment/measurement
AIR-BX1 and AIR-BX2,
BARKER [27]
Acute worsening of respiratory disease meeting ⩾3 major (or two major
and at least two minor) criteria
Major criteria were increased sputum production, change in sputum
colour, dyspnoea and cough
Minor criteria were fever (>38°C) at clinic visit, increased malaise or
fatigue, FEV1 (L) or FVC decreased by more than 10% from baseline,
and new or increased haemoptysis
TTF: median presented as
Kaplan–Meier plots
Rate: negative binomial model
Inhaled mannitol,
BILTON [29]
Worsening of signs and symptoms requiring changes in treatment Number: count
Rate: negative binomial model
TTF: Cox proportional hazard
Roxithromycin,
LIU [15]
At least four of the following nine symptoms, signs or findings: 1) change
in sputum production (consistency, colour, volume or haemoptysis); 2)
increased dyspnoea (chest congestion or shortness of breath); 3)
increased cough; 4) fever (>38°C); 5) increased wheezing; 6) decreased
exercise tolerance, malaise, fatigue or lethargy; 7) FEV1 or FVC
decreased by at least 10% from previous recorded value; 8) radiographic
changes indicative of a new pulmonary infectious process; or 9) changes
in chest sounds
TTF: Kaplan–Meier plot
Tobramycin,
ORRIOLS [13]
More frequent coughing, greater dyspnoea and increased sputum volume
and purulence
TTF: Kaplan–Meier plot
Number: count
STRATUS,
DE SOYZA [30]
Increased dyspnoea, sputum production and sputum purulence Not clear
RESPIRE I and II,
DE SOYZA [8] and
AKSAMIT [9]
Two definitions
For primary end-point: exacerbations had to meet three criteria: 1)
worsening of at least three signs or symptoms (dyspnoea, wheezing,
cough, 24-h sputum volume or sputum purulence) beyond normal
day-to-day variations for at least 2 consecutive days; 2) fever (body
temperature >38.0°C) or malaise/fatigue; and 3) systemic antibiotic
treatment
For secondary end-point: respiratory event with worsening of at least one
of the aforementioned signs or symptoms and systemic antibiotic use
TTF: (HR)
Frequency: ratio (IRR)
Number: mean
TTF: time to first; DPI: dry powder inhaler; IQR: interquartile range; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; HR:
hazard ratio; IRR: incidence rate ratio.
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of 250 mg daily azithromycin. Visits were conducted every 3 months and lung function showed statistical
difference between the treatment arm and placebo. For each 3-month interval, it was reported that FEV1
% predicted in the treatment arm increased by 1.03% while the placebo group decreased by 0.1%. The %
predicted forced vital capacity (FVC) showed a similar trend, increasing 1.33% in each 3-month interval
in the treatment arm and decreasing 0.3% in the placebo arm. BLESS was also a 12-month
placebo-controlled trial conducted in Australia [22]. The study treatment was erythromycin 400 mg twice
daily. By week 48 (end of treatment), erythromycin had reduced the rate of decline significantly in
comparison to placebo. FEV1 % predicted had declined on average by 1.6% in the treatment arm; however,
the placebo group showed a much faster decline with an average of 4.0%. The most remarkable results
came from the study by KELLETT et al. [14], who performed an 8-month crossover study between 7%
hypertonic saline and 0.9% sodium chloride for 3 months each. The 0.9% saline arms showed increases of
1.8% and 0.72% in FEV1 % predicted and FVC % predicted, respectively, whereas the treatment arm saw
large increases of 15.1% and 11.23% in FEV1 and FVC % predicted. Such a high increase sets this study
out from the rest and raises questions about the characteristics of the included patients as other studies of
hypertonic saline have not demonstrated similar improvements.
Most of the reviewed studies did not observe a change in FEV1 or other lung function parameters.
Descriptions of the methods used for spirometry were lacking in most studies, including which guidelines
were being followed. This has significant effects on reproducibility as there are substantial differences
across % predicted calculations. The test itself is both technician and patient dependent, and as patients do
not complain of reduced lung function, the clinical relevance of a change in this end-point is not known.
With respect to this view, many treatments are not designed to improve lung function, i.e. they are not
bronchodilators.
To date, lung function has not been found to be responsive in bronchiectasis in a manner similar to that
observed in COPD and CF and does not appear to be a useful efficacy end-point. Further research on the
prognosis of spirometry in relation to patient health status is required if lung function is to continue being
used as a clinical trial end-point.
QoL and symptom questionnaires
The QoL of bronchiectasis patients can be evaluated using self-completed questionnaires. The
questionnaires that we identified as being used in bronchiectasis trials were St George’s Respiratory
TABLE 6 Potential solutions to problems found in the current end-points
Current trial
end-points
Problems identified Possible solutions
Exacerbations Lack of definition
Seasonal effects in short-term studies
Variable patient reporting including underreporting
Validate EMBARC/BRR definition
Study the impact of this on exacerbation reporting
Patient diaries or symptom scales to capture nonreported
exacerbations
Develop an exacerbation prediction tool
Microbiology Unknown clinical benefit Study the correlation of microbiome with clinical burden
Sputum Dependent on patient compliance
Inter- and intra-day variation
Develop a scale indicating burden of expectoration rather than
specific volumes, weights, etc.
Alternative methods of measuring airway clearance,
e.g. imaging
Lung function Multiple guidelines
Patient and technician dependent
Therapies are not designed to improve lung function
Patients do not ask for improvement
Improve reporting and standardisation of methods
Study the impact of lung function on quality of life
Qualitative data gathering on what quality of life means to
patients themselves
Identify patient subgroups who show lung function
improvements in response to therapies as in cystic fibrosis
HRQoL
(questionnaires)
Multiple variations
Currently anchored to clinical markers with no
validated significance in bronchiectasis patients
Not shown to be responsive
Further validation required
Further work may involve optimising existing questionnaires
or developing new responsive scales
Establish MCID specific for bronchiectasis
Biomarkers No direct clinical benefit Remain as early phase end-point
May be useful for selecting patients for entry into trials
HRQoL: health-related quality of life; EMBARC: the European Bronchiectasis Registry; BRR: American Bronchiectasis Research Registry;
MCID: minimal clinically important difference.
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Questionnaire (SGRQ), Quality of Life – Bronchiectasis (QOL-B) and Leicester Cough Questionnaire
(LCQ). A further bronchiectasis QoL questionnaire has been described in the literature but we did not
find any trials to have used this tool as yet, the Bronchiectasis Health Questionnaire (BHQ) [33–36]. Most
questionnaires have only been minimally validated in bronchiectasis and all except the QOL-B and BHQ
were not specifically designed for bronchiectasis.
Clinical trials have failed to show improvements in QoL, despite it being the most commonly used end-point
and SGRQ being used most often in bronchiectasis trials [37]. However, the validity of current questionnaires
such as SGRQ and QOL-B are becoming frequently challenged as more trials show positive outcomes in
areas such as exacerbations but lack the correlation in patient responses [13, 21–23, 26, 30, 31].
Five studies used HRQoL for their primary end-point with only one demonstrating a statistically
significant difference when compared with placebo [26], although there was a statistically significant
improvement in the AIR-BX2 study of inhaled aztreonam it did not reach the MCID [27].
More interestingly, following the failure of a trial in 6% hypertonic saline to show superiority over 0.9%
placebo, NICOLSON et al. [16] reported 29 (72.5%) of the study participants chose to remain on nebulised
saline after study completion suggesting there was an overall acceptance and perception of benefit despite
a significant decrease in self-reported compliance after 6 months and failure of the study to meet any
end-points. This trial included SGRQ and LCQ as QoL measures [16].
Conversely, some studies have shown the opposite effect with improvement from a patient perspective
despite failing due to quantitative findings in the primary end-points [24, 25, 29].
From the 23 studies we reviewed, only three had a positive primary end-point with a corresponding
positive HRQoL result [12, 15, 28]. There was a disconnect between QoL tools and exacerbation reduction,
but also a surprising disconnect in the RESPIRE trials of inhaled dry powder ciprofloxacin where two
tools designed to measure symptoms (QOL-B and SGRQ) showed divergent results. RESPIRE1 saw a
significant improvement in SGRQ scores for both the 14-day and 28-day on–off cycles (−7.59, p=0.0085
and −5.21, p=0.0636, respectively); however, this same improvement was not seen in the RESPIRE2 trial
(−1.40, p=0.5446 and −1.44, p=0.5302, respectively) [8, 9]. In neither RESPIRE1 nor RESPIRE2, and for
neither the 14-day nor the 28-day on–off cycle, were there any improvements measured by QOL-B. This
suggests there is a need for further research into the representativeness and responsiveness of
questionnaires in bronchiectasis.
Biomarkers (sputum and blood)
Biomarkers measured in RCTs include neutrophil markers and cytokines, such as interleukin (IL)-8, IL-1β,
C-reactive protein and tumour necrosis factor-α, in sputum or serum. 12 out of the 23 reviewed studies
contained biomarker end-points, with only three of these producing statistically beneficial outcomes.
Of the four studies using biomarkers for primary end-points, half produced statistically significant results
[15, 30]. Biomarkers are an area of growing interest and will probably be used more frequently in future
studies especially as assays become more clearly validated and practical to perform.
Because the FDA and European regulators require end-points that reflect how a patient feels function and
survives, biomarkers are only ever likely to be early surrogate end-points.
Other
Some trials had primary end-points which fell under this “other” category, e.g. cough, computed
tomography changes and number of symptoms [15, 16]. These studies investigated changes in nitric oxide,
nitrites and nitrates when treated with azithromycin and bronchus remodelling measured radiographically
by the changes in wall thickening due to roxithromycin. The latter trial was regarded as positive in that it
met the primary end-point with a statistically positive outcome and was the only trial in the review to
show positive results in all end-points used. The remaining “other” end-points in use included exercise
tolerance tests (6-min walk test and incremental field walking test) and the remaining trial monitored the
number of bronchiectasis symptoms using a 0–3 scale [17].
Discussion
This systematic review has described the most frequently used end-points in bronchiectasis trials and
identified those which have been most responsive to intervention. It is crucial to re-evaluate the conduct of
bronchiectasis clinical trials in view of the failure of multiple recent large-scale trials to achieve consistent,
statistically significant results. While it is possible that these trials represent appropriate failures because
the drugs are ineffective, this seems unlikely since the majority of these drug therapies are either used in
clinical practice with subjective patient benefit or have been shown to improve outcomes in CF or other
diseases. Alternative hypotheses for the repeated challenges in bronchiectasis trials are therefore that the
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disease is too heterogeneous and therefore the responsive populations have not been identified, or that the
clinical trial end-points have not been sufficiently characterised and defined. Our review focuses on this
latter point which is crucial for future trial design.
As bronchiectasis has been a neglected disease, trial design has borrowed heavily from CF and COPD.
There is limited longitudinal data for bronchiectasis patients and therefore little is known about disease
prognosis. WELSH et al. [38] produced an overview of Cochrane systematic reviews and clearly concluded
the need for a national or international organisation with patient values at its core and highlighted the
need for developing improved outcome measures for future research. In September 2017, the ERS released
the first bronchiectasis guidelines which were approved by an international patient advisory group [3]. The
guidelines confirmed the nine most important Patient/problem, Intervention, Comparison, Outcome
(PICO) topics agreed between patients and clinicians (aetiology, exacerbations, eradication, long-term
anti-inflammatories, long-term antibiotics, long-term mucoactives, long-term bronchodilators, thoracic
surgery and respiratory physiotherapy). These topics were unanimously decided as the most important
factors and therefore it makes sense to develop future study outcomes with these in mind.
CHALMERS et al. [37] reviewed 10 major bronchiectasis RCTs and ran a population of 1672 patients
through the main inclusion and exclusion criteria of each trial. The outcome of this showed the high
selectivity of RCTs do not represent the general bronchiectasis population as up to 93% of the reviewed
population were not eligible for some of the studies. The group expressed their concern about licensing
therapies based on this evidence; underestimating the efficacy of a drug and not licensing it despite the
possibility of a positive result if a wider cohort had been used, or overestimating the efficacy leading to a
licence and distribution to a population of bronchiectasis patients where there is no evidence of benefit [37].
Table 6 summarises the main end-point categories we have reviewed, and which should produce outcomes
fitting both patient PICO expectations and the FDA requirement. The table also summarises initial
possible approaches to optimising each end-point.
Currently there is no validated exacerbation prediction tool and therefore studies are hard to power
accurately for this end-point. Clinically, a frequent exacerbator will have three or more exacerbations in a
12-month period [3]; however, eligibility to these studies usually only requires one documented
exacerbation requiring antibiotics which is neither representative of the patient population nor likely to
capture an event during the study period. Reviewing only the past 12 months of patients’ exacerbation
history could risk overestimating the severity of patients and prevent true reflection of any clinical benefit
a therapy may have. Another critical issue that has not been addressed in these trials is the potential
underreporting of exacerbations by patients. The exacerbation threshold (the point at which a patient seeks
medical help) will vary from patient to patient.
In summary, exacerbations are a very important end-point, but insufficient research has been performed
to understand how they should be defined, detected in trials, and to account for potential confounders in
trials such as seasonality, underpowering and underreporting. We identified a high degree of heterogeneity
in exacerbation analysis. There is an emerging consensus that exacerbation frequency is the most clinically
relevant end-point, not least because it correlates with clinically important outcomes such as mortality and
hospitalisation. However, even analysis of the frequency end-point is not straightforward as the negative
binomial modelling approach which is most frequently used makes some assumptions, such as that
exacerbations are independent events, which we know are not true. Alternative analysis approaches to
exacerbation modelling such as the ANDERSEN and GILL [39] “counting process” may be advantageous and
better reflect the biology of the disease.
It is true that research should be centred on the patient and that patients will best answer whether there is
a positive difference between an active intervention and a control. The most likely way of capturing this
result is through HRQoL or symptom questionnaires.
DUDGEON et al. [40] conducted a qualitative study asking eight bronchiectasis patients to review the
standard questionnaires (SGRQ, QOL-B, LCQ and COPD Assessment Test). The results showed a
remarkable agreement in that none of the questionnaires captured a “baseline” result for later comparison.
The patients themselves did not understand how the questions could assess changes in their health
without this information. In addition to this, recall and content were most relevant to the reviewers.
A 1-week recall time in the QOL-B was preferred over the 24 h in LCQ or 3 months in the SGRQ.
The patients also preferred questionnaires with multiple choice or Likert scale answers as opposed to true
and false options, again reflecting the heterogeneity of approaches to measuring symptoms and HRQoL in
bronchiectasis.
In most cases the MCIDs for end-points in bronchiectasis have not been defined. It is important that a
thorough evaluation of end-points for bronchiectasis is undertaken to better design future trials and
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understand their results. We also urge the companies and investigators that have undertaken trials in
bronchiectasis to make their datasets available to academic researchers in order that we can learn from
prior studies and to better inform future trial design.
Our review has limitations. We focused only on adequately powered efficacy and safety studies of
pharmacotherapies and our results should not be generalised to airway clearance or other studies in
bronchiectasis. We included an arbitrary cut-off of 25 subjects enrolled to the selected studies, but
acknowledge that it is theoretically possible to have informative data from smaller studies.
Conclusion
This systematic review identified which end-points are used in bronchiectasis trials, which have been
shown to be responsive to intervention and identified gaps and research priorities in our understanding of
bronchiectasis end-points.
This systematic review demonstrates a need for guidance to standardise definitions and design features to
improve reproducibility and increase the likelihood of demonstrating statistically significant benefits with
new therapies.
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